The Lynx Group


An investigational first-in-class ­anticancer quinolone derivative, vosaroxin, extended median over­­all survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refrac­­tory acute myeloid leukemia (AML), although the difference was not significant.
Read Article

San Francisco, CA—In patients with acute lymphoblastic leukemia (ALL), assessment of minimal residual disease (MRD) is increasingly used to evaluate response to treatment. An antibody that recruits the body’s T-cells to attack MRD in patients with ALL whose disease is in remission can prevent full relapse.
Read Article

New Orleans, LA—Mounting evidence from several research centers shows that autologous T-cells genetically engineered with a chimeric antigen receptor-T (CAR-T; also called CTL019) achieve dramatic responses in patients with advanced leukemia and lymphoma who have exhausted all treatment options.
Read Article

A long-standing treatment standard for indolent non-Hodgkin lymphoma (NHL) has fallen victim to the chopping block, so to speak, at least in Germany.
Read Article

Children with acute lymphoblastic leukemia (ALL) had no drop-off in efficacy with an anthracycline-free regimen that also reduced the long-term risk of cardiotoxicity, reported Andre Baruchel, MD, PhD, Chief of Pediatric Hematology, Robert Debré University Hospital, Paris, France.
Read Article

Page 6 of 6

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: